Coherus Oncology (CHRS) Change in Accured Expenses (2013 - 2026)

Coherus Oncology has disclosed Change in Accured Expenses across 14 years of filings, most recently posting $33000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $33000.0, up 100.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$841000.0 (up 98.72% YoY), and the FY2025 annual result was -$9.2 million, up 83.83% from the prior year.
• Change in Accured Expenses came in at $33000.0 for Q1 2026 at Coherus Oncology, down from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $44.8 million in Q3 2024 to a low of -$55.8 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $33000.0 (2026), against an average of -$3.2 million.
• Across the five-year window, Change in Accured Expenses surged 828.69% in 2023 and sank 1612.38% in 2024, its largest moves.
• Coherus Oncology's Change in Accured Expenses stood at -$31.7 million in 2022, then soared by 111.64% to $3.7 million in 2023, then tumbled by 1612.38% to -$55.8 million in 2024, then soared by 107.95% to $4.4 million in 2025, then sank by 99.26% to $33000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $33000.0 (Q1 2026), $4.4 million (Q4 2025), and -$6.3 million (Q3 2025), per Business Quant data.